Search | OpenScholar

Search results

374 results found

Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. J Parkinsons Dis 2015;5:773-82.

Publication: Journal Article

Bega, D, S Kim, Y Zhang, J Elm, J Schneider, R Hauser, A Fraser, and T Simuni. 2015. “Predictors of Functional Decline in Early Parkinson’s Disease: NET-PD LS1 Cohort. J Parkinsons Dis 2015;5:773-82.”. J Parkinsons Dis.

Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:268-75.

Publication: Journal Article

Low, PA, D Robertson, S Gilman, H Kaufmann, W Singer, I Biaggioni, R Freeman, et al. 2014. “Efficacy and Safety of Rifampicin for Multiple System Atrophy: A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Neurol 2014;13:268-75.”. Lancet Neurol.

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey. Parkinsons Dis. 2021 Feb 19;2021:6638088. doi: 10.1155/2021/6638088. eCollection 2021.PMID: 33688424

Publication: Journal Article

Hauser, RA, G Banisadr, K Vuong, D Freilich, S Fisher, and R D’Souza. 2021. “Real-World Experience With Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey. Parkinsons Dis. 2021 Feb 19;2021:6638088. Doi: 10.1155/2021/6638088. ECollection 2021.PMID: 33688424”. Parkonsons Dis.

Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease. Evid Based Med 2015;20:17.

Publication: Journal Article

Hauser, RA. 2015. “Initial Choice of Medication Has Little Effect on Short-Term or Long-Term Outcome for Most Patients With Parkinson’s Disease. Evid Based Med 2015;20:17.”. Evid Based Med.

Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. Mov Disord 2015;30:589-92.

Publication: Journal Article

Poewe, W, RA Hauser, and A Lang. 2015. “Effects of Rasagiline on the Progression of Nonmotor Scores of the MDS-UPDRS. Mov Disord 2015;30:589-92.”. Mov Disord.

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet 2019;58:77-88.

Publication: Journal Article

Hauser, RA, R Pahwa, WA Wargin, CJ Souza-Prien, N McClure, R Johnson, JT Nguyen, R Patni, and GT Went. 2018. “Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet 2019;58:77-88.”. Clin Pharmacokinet.

Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord 2016;33:127-133.

Publication: Journal Article

Wills, AA, JJ Elm, R Ye, KL Chou, SA Parashos, RA Hauser, I Bodis-Wollner, et al. 2016. “Cognitive Function in 1736 Participants in NINDS Exploratory Trials in PD Long-Term Study-1. Parkinsonism Relat Disord 2016;33:127-133.”. Parkinsonism Relat Disord.

Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014; Parkinsons Dis 2014;2014:467131.

Publication: Journal Article

Hauser, RA, MF Gordon, Y Mizuno, W Poewe, P Barone, AH Schapira, O Rascol, C Debieuvre, and M Fradorf. 2014. “Minimal Clinically Important Difference in Parkinson’s Disease As Assessed in Pivotal Trials of Pramipexole Extended Release. Parkinsons Dis. 2014; Parkinsons Dis 2014;2014:467131.”. Parkinsons Dis.

Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord 2014;29:1171-80.

Publication: Journal Article

Goldman, SM, F Kamel, GW Ross, SA Jewell, C Marras, JA Hoppin, DM Umbach, et al. 2014. “Peptidoglycan Recognition Protein Genes and Risk of Parkinson’s Disease. Mov Disord 2014;29:1171-80.”. Mov Disord.

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 2014;13:767-76.

Publication: Journal Article

Hauser, RA, CW Olanow, KD Kieburtz, E Pourcher, A Docu-Axelerad, M Lew, O Kozyolkin, et al. 2014. “Tozadenant (SYN115) in Patients With Parkinson’s Disease Who Have Motor Fluctuations on Levodopa: A Phase 2b, Double-Blind, Randomised Trial. Lancet Neurol 2014;13:767-76.”. Lancet Neurol.